Navigation Links
Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease
Date:2/21/2012

LOS ANGELES (Feb. 20, 2012) A Cedars-Sinai research scientist has been awarded two national grants totaling more than $2.5 million, including a prestigious Research Project Grant from the National Institutes of Health to study potential treatments for Alzheimer's disease.

Terrence Town, PhD, is studying drugs that potentially could disrupt the formation and accumulation of sticky amyloid plaques that build up in the brain and are widely considered a root cause of Alzheimer's disease, a chronic and fatal condition that impairs memory and cognition. In the disease's final stages, patients require round-the-clock care.

Amyloid is an abnormal protein usually produced in the bone marrow that can be deposited in any tissue or organ. An unhealthy buildup of the protein is believed to lead to diseases such as Alzheimer's.

"Alzheimer's has the potential to bankrupt this country,'' said Town, PhD, the studies' principal investigator and research scientist in the Cedars-Sinai Regenerative Medicine Institute and the Departments of Biomedical Sciences and Neurosurgery. "It is the public health crisis of our time and the big question is: what are we going to do about it? Our approach is to target the body's immune system to clean up amyloid plaques and thereby allow brain regeneration."

The NIH grant totals more than $2 million over five years and is earmarked for the study of macrophages, common cells that circulate in the blood and are capable of clearing damaging substances, such as plaques.

"Our goal is to identify drugs that give the signal to macrophages to enter the brain and eat away at the amyloid plaque buildup," said Town, the Ben Winters Chair in Regenerative Medicine. "These macrophages have a central mission in life: to eat noxious substances. But because the brain is somewhat shielded from the immune system, peripheral macrophages are given the message not to go into the brain and eat the amyloid plaques. So, if we could identify what's blocking this beneficial response in these cells, the hope is that a drug would enable the macrophages to leave the blood, go into the brain and remove the plaques."

The second grant, for $550,000, was awarded by the American Federation of Aging Research and will enable Town and his team of researchers to study new ways to reduce brain inflammation.

"Understanding this important area of neuroimmunology will likely lead to new therapeutic targets for Alzheimer's,'' Town said.

The author of more than 90 scientific publications, Town is a well-known neuroimmunologist whose research focuses on understanding and treating neurologic disorders including Alzheimer's, viral encephalitis and stroke.

According to the Alzheimer's Association, more than 5.4 million Americans have the disease, and its incidence is on the rise. Alzheimer's destroys brain cells, causing memory, thinking and behavioral problems severe enough to affect work, family and social relationships. It eventually affects the basics of daily living, is incurable and, ultimately, is fatal. Alzheimer's is the sixth-leading cause of death in the United States and the fifth-leading cause for people 65 and older, association statistics show.


'/>"/>

Contact: Sally Stewart
Sally.stewart@cshs.org
310-248-6566
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Moderate red wine drinking may help cut womens breast cancer risk, Cedars-Sinai study shows
2. Cedars-Sinai study: How does a good protein hurt brain cells after clot-induced stroke?
3. TGen and Virginia G. Piper Cancer Center form drug development collaboration with Cedars-Sinai
4. Cedars-Sinai scientists, physicians to be key presenters at World Stem Cell Summit
5. Cedars-Sinai movement disorders expert on international task force for dystonia treatment
6. Latest data from Cedars-Sinai vaccine study supports immune targeting of brain tumors
7. Cedars-Sinais mobile medical clinics receive $500,000 grant from California Community Foundation
8. Cedars-Sinai to hold first annual conference on stem cell therapies for neurological disorders
9. Cedars-Sinais mobile medical clinics receive grant from George Hoag Family Foundation
10. Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies
11. Cedars-Sinai Medical Genetics Institute director honored with lifetime achievement award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... ... , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is ... treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients ... or both jaw bones. This surgery is performed to correct the alignment of the jaw. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
Breaking Medicine Technology: